ICU Medical (NASDAQ:ICUI) released its earnings results on Thursday. The medical instruments supplier reported $1.85 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.34, Briefing.com reports. ICU Medical had a net margin of 5.93% and a return on equity of 12.78%. The firm had revenue of $327.20 million during the quarter, compared to analyst estimates of $334.97 million. During the same period last year, the business earned $1.12 earnings per share. The business’s revenue was down 4.7% on a year-over-year basis. ICU Medical updated its FY 2018 guidance to $8.45-8.85 EPS and its FY18 guidance to $8.45-8.85 EPS.
NASDAQ ICUI traded down $28.23 during mid-day trading on Friday, reaching $232.01. The stock had a trading volume of 689,193 shares, compared to its average volume of 181,891. ICU Medical has a 1 year low of $196.33 and a 1 year high of $321.70. The firm has a market cap of $5.31 billion, a P/E ratio of 35.99 and a beta of 0.65.
In other ICU Medical news, VP Virginia Ruth Sanzone sold 787 shares of ICU Medical stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $303.12, for a total value of $238,555.44. Following the completion of the sale, the vice president now owns 1,367 shares of the company’s stock, valued at approximately $414,365.04. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Pfizer Inc sold 700,000 shares of ICU Medical stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $284.35, for a total transaction of $199,045,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 711,920 shares of company stock valued at $202,651,956. 12.50% of the stock is owned by company insiders.
A number of equities analysts recently weighed in on ICUI shares. TheStreet upgraded shares of ICU Medical from a “c+” rating to a “b+” rating in a report on Monday, August 20th. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “strong-buy” rating and set a $337.00 price objective for the company in a report on Wednesday, August 15th. ValuEngine lowered shares of ICU Medical from a “strong-buy” rating to a “buy” rating in a report on Friday, August 3rd. Finally, BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 28th.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
See Also: Dollar Cost Averaging
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.